Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive valuations for the Indian market.
Cipla shares jumped 4% after Citi initiated a 'Buy' rating and a 90-day Positive Catalyst Watch. Citi anticipates growth from potential US approvals for gFlovent and gVentolin, coupled with a US business rebound. Strong domestic performance, especially in respiratory, and…
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.